Unnamed: 0,title,date,stock,sentiment
780128.0,"HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $3",2020-05-27 06:57:00-04:00,LPCN,neutral
780129.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.,2020-05-18 10:23:00-04:00,LPCN,positive
780130.0,Lipocine Announces Presentations On TLANDO At AUA Virtual Experience 2020 May 15-17,2020-05-15 08:01:00-04:00,LPCN,neutral
780131.0,Lipocine Highlights Results Of Pre-Clinical Study Of LPCN 1144,2020-05-13 08:06:00-04:00,LPCN,neutral
780132.0,"Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.",2020-05-07 11:25:00-04:00,LPCN,positive
780133.0,"Lipocine Q1 EPS $(0.140), Same YoY",2020-05-07 08:01:00-04:00,LPCN,neutral
780134.0,Lipocine Reports FDA Clears LPCN 1148 Investigational New Drug Application For Phase 2 Cirrhosis Trial,2020-05-05 08:07:00-04:00,LPCN,positive
780135.0,Lipocine Announces FDA Has Denied Oral Testosterone Ester Citizen Petition Filed By Clarus Therapeutics,2020-04-17 08:07:00-04:00,LPCN,negative
780136.0,"Lipocine Reports US Appeals Court Affirmed Decision By Patent Trial, Appeal Board",2020-04-09 08:13:00-04:00,LPCN,neutral
780137.0,Lipocine Says 'No ultimate determination of infringement or validity of the patents has been determined at this point.' In Patent Infringement Suit Against Clarus,2020-03-26 08:14:00-04:00,LPCN,negative
780138.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,LPCN,neutral
780139.0,Lipocine Q4 EPS $(0.5) Up From $(0.55) YoY,2020-03-13 08:05:00-04:00,LPCN,neutral
780140.0,"Lipocine Announces TLANDO PDUFA Date Of August 28, 2020",2020-03-04 08:02:00-05:00,LPCN,neutral
780141.0,24 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-26 08:01:00-05:00,LPCN,neutral
780143.0,Lipocine shares are trading lower after the company announced a registered direct offering of 10.08 million units priced at $0.595 per unit.,2020-02-25 08:50:00-05:00,LPCN,neutral
780144.0,Lipocine Reports $6M Registered Direct Offering Priced At The Market: ~10.08M Class A Units Priced At $0.595/Unit,2020-02-25 08:31:00-05:00,LPCN,neutral
780145.0,Lipcine Says the FDA is Satisfied with its Approach to Collect Data for the Resubmission of TLANDO,2020-02-24 07:00:00-05:00,LPCN,positive
780146.0,Lipocine Receives Patent Titled 'Testosterone undecanoate compositions',2020-02-19 09:42:00-05:00,LPCN,neutral
780147.0,"Lipocine Reports Voluntary Dismissal Of Allegations Of Patent Infringement for Expired US Patents '463, '988 Related To Clarus Therapeutics",2020-02-11 16:27:00-05:00,LPCN,negative
780148.0,Lipocine 13G Filing From Hudson Bay Capital Shows 9.99% Stake,2020-02-06 15:30:00-05:00,LPCN,neutral
780149.0,20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session,2020-01-27 12:26:00-05:00,LPCN,neutral
780150.0,14 Drug Manufacturers—Specialty & Generic Stocks Moving In Thursday's Session,2020-01-23 12:52:00-05:00,LPCN,neutral
780151.0,18 Drug Manufacturers—Specialty & Generic Stocks Moving In Wednesday's Session,2020-01-22 13:28:00-05:00,LPCN,neutral
780152.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-07 07:53:00-05:00,LPCN,neutral
780153.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-01-06 07:38:00-05:00,LPCN,neutral
780154.0,"Lipocine Chairman Patel Buys 40,000 @$0.38",2020-01-02 11:26:00-05:00,LPCN,neutral
780155.0,Lipocine Received Notice From Nasdaq Stating Bid Price Of Common Stock For Last 30 Trading Days Closed Below Requirement,2019-12-27 16:08:00-05:00,LPCN,neutral
780156.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,LPCN,positive
780157.0,Stocks That Hit 52-Week Lows On Monday,2019-12-16 10:33:00-05:00,LPCN,negative
780158.0,Stocks That Hit 52-Week Lows On Friday,2019-12-13 12:22:00-05:00,LPCN,negative
780159.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,LPCN,positive
780160.0,Stocks That Hit 52-Week Lows On Thursday,2019-12-12 10:38:00-05:00,LPCN,negative
780161.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,LPCN,positive
780162.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-11 07:54:00-05:00,LPCN,neutral
780163.0,Lipocine 13G Filing From Sabby Shows New 8.74% Stake,2019-11-22 09:24:00-05:00,LPCN,neutral
780164.0,The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down,2019-11-17 08:42:00-05:00,LPCN,neutral
780165.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,LPCN,negative
780166.0,70 Biggest Movers From Yesterday,2019-11-15 05:29:00-05:00,LPCN,neutral
780167.0,Mid-Afternoon Market Update: Contura Energy Drops Following Q3 Results; International Game Technology Shares Surge,2019-11-14 14:21:00-05:00,LPCN,positive
780168.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-11-14 12:18:00-05:00,LPCN,neutral
780169.0,Mid-Day Market Update: Opera Rises After Strong Q3 Results; LiqTech International Shares Fall,2019-11-14 12:00:00-05:00,LPCN,positive
780170.0,Stocks That Hit 52-Week Lows On Thursday,2019-11-14 11:11:00-05:00,LPCN,negative
780171.0,Lipocine Prices Offering Of 10.45M Class A Units And 1.55M Class B Units At $0.50/Class A Unit And $0.4999/Class B Unit,2019-11-14 09:09:00-05:00,LPCN,neutral
780172.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,LPCN,positive
780173.0,19 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-14 07:35:00-05:00,LPCN,neutral
780174.0,30 Stocks Moving in Thursday's Pre-Market Session,2019-11-14 07:29:00-05:00,LPCN,neutral
780175.0,"11 Stocks To Watch For November 14, 2019",2019-11-14 04:25:00-05:00,LPCN,neutral
780176.0,Lipocine shares are trading lower after the company reported a common stock offering of no disclosed size.,2019-11-13 16:09:00-05:00,LPCN,negative
780177.0,"Lipocine Reports Offering Of Common Stock, Warrants, No Size Disclosed",2019-11-13 16:00:00-05:00,LPCN,negative
780178.0,"Lipocine Q3 EPS $(0.12), Same YoY",2019-11-12 16:00:00-05:00,LPCN,neutral
780179.0,6 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-12 07:41:00-05:00,LPCN,neutral
780180.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,LPCN,neutral
780181.0,58 Biggest Movers From Yesterday,2019-11-12 04:25:00-05:00,LPCN,neutral
780182.0,Mid-Afternoon Market Update: Qurate Retail Gains On Upbeat Earnings; ASLAN Pharmaceuticals Shares Slide,2019-11-11 14:45:00-05:00,LPCN,positive
780183.0,38 Stocks Moving In Monday's Mid-Day Session,2019-11-11 12:10:00-05:00,LPCN,neutral
780184.0,Mid-Day Market Update: Carbonite Jumps Following Acquisition News; Lipocine Shares Plummet,2019-11-11 12:00:00-05:00,LPCN,positive
780185.0,Stocks That Hit 52-Week Lows On Monday,2019-11-11 10:45:00-05:00,LPCN,negative
780186.0,Mid-Morning Market Update: Markets Open Lower; SunPower To Receive $298 Million Equity In Company Split,2019-11-11 10:12:00-05:00,LPCN,negative
780187.0,Lipocine's Male Hormone Therapy Stumbles With FDA For The Third Time,2019-11-11 09:06:00-05:00,LPCN,neutral
780188.0,"Benzinga Pro's Top 5 Stocks To Watch For Mon., Nov. 11, 2019: WBA, LPCN, NXTC, SPWR, TME",2019-11-11 09:04:00-05:00,LPCN,positive
780189.0,"Lipocine Receives Complete Response Letter from the FDA for its New Drug Application for TLANDO, FDA Says the Efficacy Trial Did Not Meet the Three Secondary Endpoints for Maximal Testosterone Concentrations",2019-11-11 06:35:00-05:00,LPCN,neutral
780190.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,LPCN,neutral
780191.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-01 08:21:00-04:00,LPCN,neutral
780192.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2019-11-01 08:05:00-04:00,LPCN,neutral
780193.0,51 Biggest Movers From Friday,2019-10-28 05:27:00-04:00,LPCN,neutral
780194.0,54 Biggest Movers From Yesterday,2019-10-17 05:52:00-04:00,LPCN,neutral
780195.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-10-16 12:35:00-04:00,LPCN,neutral
780196.0,71 Biggest Movers From Yesterday,2019-09-12 05:33:00-04:00,LPCN,neutral
780197.0,Stocks That Hit 52-Week Highs On Monday,2019-09-09 12:43:00-04:00,LPCN,neutral
780198.0,Stocks That Hit 52-Week Highs On Thursday,2019-09-05 12:29:00-04:00,LPCN,neutral
780199.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,LPCN,positive
780200.0,Lipocine Announces Patent Infringement Trial With Clarus Will Begin Aug. 4 2020,2019-08-27 08:02:00-04:00,LPCN,negative
780201.0,"Lipocine Withdraws Preliminary Injunction Threat Against Marketing Of Clarus Therapeutics' Jatenzo Product, Trial Date Set For August 2020",2019-08-26 08:34:00-04:00,LPCN,negative
780202.0,Stocks That Hit 52-Week Highs On Friday,2019-08-23 10:33:00-04:00,LPCN,neutral
780203.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-22 10:32:00-04:00,LPCN,neutral
780204.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,LPCN,positive
780205.0,60 Biggest Movers From Yesterday,2019-08-22 05:12:00-04:00,LPCN,neutral
780206.0,Lipocine Q2 EPS $(0.14) Beats $(0.16) Estimate,2019-08-07 09:06:00-04:00,LPCN,neutral
780207.0,"Lipocine Receives FDA Clearance For Clinical Testing Of Its NASH Candidate, LPCN 1144, In Expanded Target Population",2019-07-23 08:04:00-04:00,LPCN,neutral
780208.0,18 Stocks Joining The Russell Indices,2019-06-28 14:19:00-04:00,LPCN,neutral
780209.0,"Lipocine Set To Join Russell Microcap Index , Effective Jul. 1",2019-06-25 08:04:00-04:00,LPCN,positive
780210.0,"Lipocine Announces TLANDO NDA PDUFA Action Date Of November 9, 2019",2019-05-14 08:21:00-04:00,LPCN,neutral
780211.0,"Lipocine Q1 EPS $(0.14), Inline",2019-05-08 08:04:00-04:00,LPCN,neutral
780212.0,48 Biggest Movers From Friday,2019-04-15 07:06:00-04:00,LPCN,neutral
780213.0,Clarus Therapeutics Has Refuted Patent Infringement Complaint By Lipocine,2019-04-03 10:07:00-04:00,LPCN,negative
780214.0,Lipocine Seeks An Injunction Against The Marketing Of Clarus Therapeutics' Jatenzo For Testosterone Replacement Therapy,2019-04-03 09:34:00-04:00,LPCN,neutral
780215.0,Lipocine Shares Tick Lower As Traders Circulate FDA Access Data Doc Showing Approval For Competitor Clarus Therapeutics' Jatenzo,2019-03-27 14:44:00-04:00,LPCN,positive
780216.0,Lipocine Announces ABPM Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy,2019-03-27 08:05:00-04:00,LPCN,positive
780217.0,Lipocine Reports Acceptance Of Abstract Of Late-Breaker Presentation On LPCN 1144 Results As Part Of EASL,2019-03-26 08:08:00-04:00,LPCN,positive
780218.0,Lipocine Reports Has Been Selected To Present LPCN 1144 Results at ENDO 2019,2019-03-14 08:11:00-04:00,LPCN,neutral
780219.0,68 Biggest Movers From Yesterday,2019-03-14 05:22:00-04:00,LPCN,neutral
780220.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-03-13 12:41:00-04:00,LPCN,neutral
780221.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Mar. 13, 2019",2019-03-13 08:52:00-04:00,LPCN,positive
780222.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Mar. 12, 2019",2019-03-12 13:35:00-04:00,LPCN,positive
780223.0,Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate,2019-03-12 09:40:00-04:00,LPCN,positive
780224.0,Lipocine shares are trading higher after the company announced that its LPCN 1144 NASH Therapy demonstrated substantial fatty liver resolution and meaningful liver fat reduction in a 16-week liver fat study.,2019-03-12 09:11:00-04:00,LPCN,positive
780225.0,Lipocine's LPCN 1144 For NASH Demonstrated Substantial Fatty Liver Resolution And Meaningful Liver Fat Reduction In 16-Week Liver Fat Study,2019-03-12 08:08:00-04:00,LPCN,positive
780226.0,Lipocine Announces Its LPCN 1144 NASH Therapy Demonstrated Substantial Fatty Liver Resolution And Meaningful Liver Fat Reduction In NAFLD Population,2019-03-12 08:02:00-04:00,LPCN,positive
780227.0,"Lipocine Q4 EPS $(0.55) Misses $(0.13) Estimate, Sales $428.031K",2019-03-06 08:12:00-05:00,LPCN,negative
780228.0,Lipocine Inc. Rpoerts FDA Clearance Of IND to Commence Phase 2 Study Of LPCN 1144 In Biopsy Confirmed NASH Subjects,2019-02-14 07:57:00-05:00,LPCN,neutral
780229.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-01-24 12:43:00-05:00,LPCN,neutral
780230.0,Lipocine shares are trading higher after the company filed an Investigational New Drug Application to initiate a Phase 2 2 study of LPCN 1144 in NASH subjects.,2019-01-24 10:30:00-05:00,LPCN,positive
780231.0,Lipocine 8-K Shows Co. Filed Investigational New Drug Application To Initiate Phase 2 Study Of LPCN 1144 In NASH With Biopsy-Confirmed NASH Subjects,2019-01-24 08:04:00-05:00,LPCN,neutral
780232.0,48 Biggest Movers From Yesterday,2019-01-18 05:06:00-05:00,LPCN,neutral
780233.0,Mid-Afternoon Market Update: Dow Turns Higher; Signet Jewelers Shares Plunge,2019-01-17 14:33:00-05:00,LPCN,positive
780234.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-01-17 12:45:00-05:00,LPCN,neutral
780235.0,Mid-Day Market Update: Insteel Industries Falls After Q1 Results; Lipocine Shares Jump,2019-01-17 12:24:00-05:00,LPCN,positive
780236.0,"Ladenburg Thalmann Is Encouraged By Lipocine's 'Positive interim LPCN 1144 proof-of-concept NASH study data showing a reduction on liver fat based on MRIs'; Reiterates Buy, $5 Target",2019-01-17 12:22:00-05:00,LPCN,positive
780237.0,'Lipocine fatty liver drug study results don't hold up to scrutiny' -STAT News,2019-01-17 12:06:00-05:00,LPCN,neutral
780238.0,Mid-Morning Market Update: Markets Mostly Lower; Morgan Stanley Earnings Miss Estimates,2019-01-17 10:19:00-05:00,LPCN,negative
780239.0,Lipocine's NASH Candidate Shows Promise In Liver Fat Study,2019-01-17 10:00:00-05:00,LPCN,positive
780240.0,Lipocine shares are trading higher after the company gave an update on its liver fat study.,2019-01-17 09:15:00-05:00,LPCN,positive
780241.0,22 Stocks Moving In Thursday's Pre-Market Session,2019-01-17 07:58:00-05:00,LPCN,neutral
780242.0,"Adam Feuerstein Bearish Tweet on Lipocine: I could conduct another webinar on clinical trial red flags based solely on todays $LPCN... Missing patients (and too few overall), no placebo control, skewed means, arbitrary data cutoffs... VKTX data way better",2019-01-17 07:36:00-05:00,LPCN,negative
780243.0,Lipocine's NASH Therapy Candidate Achieves 'Meaningful' Liver Fat Reduction Based on Interim Results,2019-01-17 07:07:00-05:00,LPCN,neutral
780244.0,USPTO Grants Priority Motion To Lipocine And Enters Judgment Against Clarus,2019-01-14 08:11:00-05:00,LPCN,positive
780245.0,Lipocine Reports Successful Ex Vivo Conversion Assessment Of TLANDO,2018-12-31 08:04:00-05:00,LPCN,positive
780246.0,Lipocine Q3 EPS $(0.12) Beats $(0.24) Estimate,2018-11-07 09:07:00-05:00,LPCN,neutral
780247.0,Lipocine Announces Completion Of Enrollment In LPCN 1144 Liver Imaging Study In Subjects At-Risk For NASH,2018-11-05 08:14:00-05:00,LPCN,neutral
780248.0,Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO,2018-11-01 16:15:00-04:00,LPCN,negative
780249.0,Lipocine Q2 EPS $(0.15) Beats $(0.25) Estimate,2018-08-07 07:49:00-04:00,LPCN,neutral
780250.0,Lipocine Announces Dosing Of First Subject In Ambulatory Blood Pressure Study For TLANDO Testosterone Replacement Therapy,2018-06-07 08:13:00-04:00,LPCN,negative
780251.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,LPCN,neutral
780252.0,Lipocine Shares Down 35.4% After The FDA Issued Complete Response Letter Saying Co.'s TRT Product TLANDO Could Not Be Approved In Current Form; FDA Identified 4 Deficiencies,2018-05-09 13:32:00-04:00,LPCN,neutral
780253.0,"Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks",2018-05-09 09:45:00-04:00,LPCN,neutral
780254.0,Benzinga Pro's 5 Stocks To Watch Today,2018-05-09 08:45:00-04:00,LPCN,neutral
780255.0,UPDATE: Lipocine Says FDA's CRL Advised New Drug Application For TLANDO Cannot Be Approved In Its Present Form; CRL Identified 4 Deficiencies,2018-05-09 07:01:00-04:00,LPCN,negative
780256.0,Lipocine Reports Received Complete Response Letter For TLANDO,2018-05-09 06:59:00-04:00,LPCN,neutral
780257.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,LPCN,neutral
780258.0,REMINDER: Lipocine Has FDA PDUFA Date for LPCN 1021 NDA,2018-05-08 07:10:00-04:00,LPCN,neutral
780259.0,"Lipocine Shares Up 3.9% After Co. Earlier Reported Lighter-Than-Expected Q1 Loss, With FDA PDUFA Date Scheduled For its LPCN 1021 NDA Tuesday",2018-05-07 12:57:00-04:00,LPCN,neutral
780260.0,"The Week Ahead: Nvidia And Dropbox Earnings, April Retail Sales, Trump Drug Pricing Speech Expected",2018-05-07 08:01:00-04:00,LPCN,neutral
780261.0,Lipocine Q1 EPS $(0.13) Beats $(0.21) Estimate,2018-05-07 08:01:00-04:00,LPCN,neutral
780262.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,LPCN,neutral
780263.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates,2018-05-01 15:39:00-04:00,LPCN,neutral
780264.0,"Seaport Global Initiates Coverage On Lipocine with Buy Rating, Announces $10.00 Price Target",2018-03-29 09:33:00-04:00,LPCN,neutral
780265.0,"Lipocine Reports FY EPS $(1.05) vs $(1.03) Est., No Sales",2018-03-12 08:15:00-04:00,LPCN,negative
780266.0,"Benzinga Pro's Top 10 Most-Searched Tickers Wed. Morning: Square, Lipocine, Macy's, Mallinckrodt, Tetraphase Pharma, Zosano Pharma, Arcadia Biosciences, DelMar Pharma, Akers Biosciences, Acorn",2018-02-28 07:17:00-05:00,LPCN,positive
780267.0,"Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating",2018-02-27 11:45:00-05:00,LPCN,positive
780268.0,Lipocine Shares Up 12.3% For Session But Well Off Pre-Market High After Empire Asset Management Upgraded Stock To Buy And Set $21 Price Target,2018-02-27 11:21:00-05:00,LPCN,positive
780269.0,Empire Asset Management Upgrades Lipocine to Buy,2018-02-27 08:12:00-05:00,LPCN,positive
780270.0,Lipocine Announces Memorandum of Understanding Settlement of Securities Class Action Lawsuit,2018-02-16 08:01:00-05:00,LPCN,positive
780271.0,5 Biggest Price Target Changes For Friday,2018-01-12 10:11:00-05:00,LPCN,neutral
780272.0,46 Biggest Movers From Yesterday,2018-01-12 05:25:00-05:00,LPCN,neutral
780273.0,Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades,2018-01-11 14:49:00-05:00,LPCN,neutral
780274.0,38 Stocks Moving In Thursday's Mid-Day Session,2018-01-11 13:18:00-05:00,LPCN,neutral
780275.0,Mid-Day Market Update: Dow Surges 150 Points; Lipocine Shares Plummet,2018-01-11 12:46:00-05:00,LPCN,positive
780276.0,Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Tops Q4 Estimates,2018-01-11 10:28:00-05:00,LPCN,positive
780277.0,"Benzinga's Top Upgrades, Downgrades For January 11, 2018",2018-01-11 09:19:00-05:00,LPCN,positive
780278.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-01-11 08:37:00-05:00,LPCN,neutral
780279.0,Canaccord Genuity Downgrades Lipocine to Hold,2018-01-11 08:20:00-05:00,LPCN,neutral
780280.0,"Lipocine Shares Resume Trade, Plunge 56.6%",2018-01-10 16:52:00-05:00,LPCN,positive
780281.0,"UPDATE: Lipocine Press Release Confirms FDA AdCom Panel Voted 6 In Favor, 13 Against Benefit/Risk Profile Of TLANDO",2018-01-10 16:51:00-05:00,LPCN,positive
780282.0,Lipocine Shares To Resume Trade At 4:50 p.m. EST,2018-01-10 16:32:00-05:00,LPCN,positive
780283.0,"UPDATE: Lipocine Says FDA Decision On Tlando NDA Expected By Assigned PDUFA Date Of May 8, 2018",2018-01-10 16:26:00-05:00,LPCN,neutral
780284.0,FDA Votes 6-13 For Benefit/Risk Profile Of Lipocine's Oral Testosterone Product Candidate,2018-01-10 16:26:00-05:00,LPCN,neutral
780285.0,Benzinga Pro's 6 Stocks To Watch Today,2018-01-10 08:27:00-05:00,LPCN,neutral
780286.0,Lipocine Shares Halted Ahead Of Adcom Meeting For LPCN 1021,2018-01-10 07:50:00-05:00,LPCN,positive
780287.0,Lipocine Shares Halted News Pending,2018-01-10 07:00:00-05:00,LPCN,positive
780288.0,REMINDER: Lipocine FDA Adcom Meeting For LPCN 1021 Takes Place Wednesday Jan. 10,2018-01-09 17:05:00-05:00,LPCN,neutral
780289.0,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In",2018-01-08 11:46:00-05:00,LPCN,neutral
780290.0,Attention Biotech Investors: Brace For These January PDUFA Events,2017-12-30 10:19:00-05:00,LPCN,neutral
780291.0,"H.C. Wainwright Assumes Lipocine at Buy, Announces price target $10.00",2017-12-08 07:17:00-05:00,LPCN,neutral
780292.0,"U.S. FDA Extends Review for Lipocine's TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged",2017-11-17 08:01:00-05:00,LPCN,positive
780293.0,Lipocine Reports Q3 EPS $(0.22) vs $(0.21) Est.,2017-11-08 08:05:00-05:00,LPCN,neutral
780294.0,"Lipocine Reports FDA Scheduled BRUDAC Meeting On Jan. 10, 2018 To Discuss NDA For TLANDO",2017-10-18 08:02:00-04:00,LPCN,neutral
780295.0,Lipocine Reports PTAB Granted Lipocine's Motion To Deny Clarus' Previously Accorded Priority Date For '428 Patent,2017-09-21 08:02:00-04:00,LPCN,negative
780296.0,"Lipocine Reports FDA Panel Meeting For TLANDO, Says Date Has Not Been Finalized But Will Occur Prior To PDUFA Goal Date Of Feb. 8, 2018",2017-09-20 08:01:00-04:00,LPCN,neutral
780297.0,Watch These 5 Huge Put Purchases In Tuesday Trade,2017-08-15 04:18:00-04:00,LPCN,positive
780298.0,Lipocine Option Alert: Feb 16 $5 Puts Sweep (18) at the Ask: 650 @ $1.851 vs 140 OI; Ref=$4.22 Signals,2017-08-14 12:12:00-04:00,LPCN,positive
780299.0,"Lipocine PDUFA Goal Date Set at Feb 8, 2018",2017-08-14 08:07:00-04:00,LPCN,neutral
780300.0,"Lipocine Q2 EPS $(0.31) vs $(0.31) Est., No Sales",2017-08-07 08:07:00-04:00,LPCN,negative
780301.0,Lipocine Releases Updated Corporate Presentation,2017-06-28 06:19:00-04:00,LPCN,neutral
780302.0,Lipocine Reports Submission of SPA on LPCN 1107,2017-06-26 08:00:00-04:00,LPCN,neutral
780303.0,Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge,2017-06-20 14:33:00-04:00,LPCN,positive
780304.0,10 Biggest Mid-Day Gainers For Tuesday,2017-06-20 12:40:00-04:00,LPCN,neutral
780305.0,Mid-Day Market Update: Crude Oil Down Over 3%; Lipocine Shares Spike Higher,2017-06-20 12:01:00-04:00,LPCN,negative
780306.0,Lipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint,2017-06-20 11:25:00-04:00,LPCN,neutral
780307.0,Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Expectations,2017-06-20 10:12:00-04:00,LPCN,positive
780308.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-06-20 08:09:00-04:00,LPCN,neutral
780309.0,Watch These 5 Huge Call Purchases In Tuesday Trade,2017-06-20 04:01:00-04:00,LPCN,positive
780310.0,Lipocine +30.5% After-Hours @$5.25 After Co Announces LPCN 1021 Met Primary Endpoint,2017-06-19 16:31:00-04:00,LPCN,neutral
780311.0,Benzinga's Option Alert Recap From June 19,2017-06-19 16:14:00-04:00,LPCN,positive
780312.0,"Lipocine Validates ""No Titration"" Dosing Regimen, Reports Positive Topline Results For LPCN 1021, Met Primary Endpoints",2017-06-19 16:01:00-04:00,LPCN,positive
780313.0,Option Alert: Lipocine Jul 5.0 Calls Sweep: 500 @  ASK  $0.75: 877 traded vs 142 OI:  Earnings 8/8 Before Open (est)  $4.02 Ref,2017-06-19 12:38:00-04:00,LPCN,positive
780314.0,Lipocine Reports Q1 EPS $(0.26) vs (0.38) In Prior Year Period,2017-05-08 08:00:00-04:00,LPCN,neutral
780315.0,Lipocine Reports FY16 EPS $(1.04) vs. Est. $(1.16),2017-03-06 16:00:00-05:00,LPCN,neutral
780316.0,Royce & Associates Report 6.45% Stake In Lipocine,2017-01-11 11:41:00-05:00,LPCN,neutral
780317.0,Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107,2017-01-09 07:10:00-05:00,LPCN,neutral
780318.0,"Lipocine Initiates Dosing Flexibility Study For LPCN 1021, Expects Top-Line Results Q2 2017",2017-01-05 08:08:00-05:00,LPCN,positive
780319.0,"Canaccord Genuity Assumes Lipocine at Buy, Announces $15.00 Target",2016-12-20 07:26:00-05:00,LPCN,neutral
780320.0,Lipocine Reports Q3 EPS $(0.18) vs $(0.30) Est.,2016-11-08 08:02:00-05:00,LPCN,neutral
780321.0,Lipocine Gets A Boost After News From The FDA,2016-10-17 10:12:00-04:00,LPCN,positive
780322.0,18 Stocks Moving In Monday's Pre-Market Session,2016-10-17 08:46:00-04:00,LPCN,neutral
780323.0,Lipocine +10.5% Premarket @$4.20; FDA Agreed to Review New Dosing Regimen for LPCN 1021,2016-10-17 08:35:00-04:00,LPCN,positive
780324.0,Lipocine's Positive Patent Lawsuit News Not Enough To Lift The Stock,2016-10-13 15:53:00-04:00,LPCN,positive
780325.0,Clarus Therapeutics Patent Infringement Lawsuit Against Lipocine Dismissed Due To Lack Of FDA Approval For LPCN-1021 And Not On Merits Of Case,2016-10-13 08:32:00-04:00,LPCN,negative
780326.0,14 Stocks Moving In Tuesday's Pre-Market Session,2016-10-11 08:33:00-04:00,LPCN,neutral
780327.0,Lipocine Still Can't Clear $6,2016-10-10 12:09:00-04:00,LPCN,negative
780328.0,Lipocine Showered With Good News Recently,2016-10-10 10:14:00-04:00,LPCN,positive
780329.0,Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ruby Tuesday Shares Fall Following Q1 Results,2016-10-07 14:56:00-04:00,LPCN,negative
780330.0,Lipocine Reports Dismissal of Patent Suit Related to LPCN 1021,2016-10-07 14:33:00-04:00,LPCN,neutral
780331.0,Technical Alert: Liopcine Leaps After New Buy Rating At H.C. Wainwright,2016-10-07 12:57:00-04:00,LPCN,positive
780332.0,10 Biggest Mid-Day Gainers For Friday,2016-10-07 12:43:00-04:00,LPCN,neutral
780333.0,Mid-Day Market Update: Dow Drops Over 100 Points; Gap Shares Rise Following September Sales Numbers,2016-10-07 12:13:00-04:00,LPCN,positive
780334.0,Mid-Morning Market Update: Markets Open Lower; Silicon Motion Raises Q3 Forecast,2016-10-07 10:11:00-04:00,LPCN,negative
780335.0,Lipocine Spikes to High of $5.90 on Volume,2016-10-07 09:31:00-04:00,LPCN,neutral
780336.0,HC Wainwright's New Buy Rating On Lipocine Suggests 500% Upside,2016-10-07 08:08:00-04:00,LPCN,neutral
780337.0,"H.C. Wainwright Initiates Coverage on Lipocine at Buy, Announces $25.00 PT",2016-10-07 07:28:00-04:00,LPCN,neutral
780338.0,"15 Stocks That Rallied 4 Days, Then Sold Off Yesterday",2016-09-29 07:13:00-04:00,LPCN,neutral
780339.0,Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade,2016-09-26 14:30:00-04:00,LPCN,positive
780340.0,Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News,2016-09-26 12:49:00-04:00,LPCN,negative
780341.0,12 Biggest Mid-Day Gainers For Monday,2016-09-26 12:10:00-04:00,LPCN,neutral
780342.0,"Bio Therapeutic Stocks Strong Today Amid News Out of Array, Lipocine, GW Pharma, Aldeyra: Summit Up 15%, Cerulean 10.5%, Clearside 10%, Aviragen 7.2%, Gemphire, Forward Pharma  5%",2016-09-26 11:46:00-04:00,LPCN,positive
780343.0,"Lipocine Reports Positive Top-Line Phase 2b Study Results for LPCN 1111, Well Tolerated With No SAE's Reported",2016-09-26 08:01:00-04:00,LPCN,positive
780344.0,30 Stocks With Three-Day Increasing Volume,2016-09-20 09:10:00-04:00,LPCN,neutral
780345.0,Lipocine Reports Q2 EPS $(0.32) vs. Est. $(0.37),2016-08-09 08:00:00-04:00,LPCN,neutral
780346.0,Lipocine To Reduce Workforce By 33%,2016-07-18 17:39:00-04:00,LPCN,neutral
780347.0,Mid-Afternoon Market Update: Dow Jumps Over 250 Points; Diamond Resorts Shares Climb Following Apollo Deal,2016-06-29 14:43:00-04:00,LPCN,positive
780348.0,7 Biggest Mid-Day Losers For Wednesday,2016-06-29 13:11:00-04:00,LPCN,negative
780349.0,Mid-Day Market Update: Crude Oil Surges 3%; Galena Biopharma Shares Tumble,2016-06-29 12:23:00-04:00,LPCN,negative
780350.0,Stocks Hitting 52-Week Lows,2016-06-29 10:42:00-04:00,LPCN,negative
780351.0,Mid-Morning Market Update: Markets Open Higher; General Mills Profit Tops Expectations,2016-06-29 10:13:00-04:00,LPCN,positive
780352.0,13 Stocks Moving In Wednesday's Pre-Market Session,2016-06-29 08:32:00-04:00,LPCN,neutral
780353.0,Lipocine -51% Premarket @$3.07 Following Announcement of CRL from FDA,2016-06-29 07:12:00-04:00,LPCN,neutral
780354.0,"Lipocine Receives Response Letter From FDA, Notes Deficiencies In Dosing Algorithm On Label",2016-06-29 06:56:00-04:00,LPCN,neutral
780355.0,Watch Out For Extreme Volatility In Lipocine On Tuesday,2016-06-27 16:28:00-04:00,LPCN,neutral
780356.0,The 5 Stocks Wall Street Is Most Confident On This Week,2016-06-24 15:57:00-04:00,LPCN,positive
780357.0,Option Alert: LPCN Jul16 7.5 Calls: 1000 @  ASK  $2.05: 1071 traded vs 657 OI:  Earnings 8/9  $6.62 Ref,2016-06-21 10:07:00-04:00,LPCN,positive
780358.0,Stocks Hitting 52-Week Lows,2016-06-20 10:30:00-04:00,LPCN,negative
780359.0,Slingshot Insights' Expert Conference Call On Lipocine,2016-06-17 15:03:00-04:00,LPCN,neutral
780360.0,Here's Why You Should Watch For Movement In Lipocine Tomorrow,2016-06-08 16:31:00-04:00,LPCN,neutral
780361.0,Lipocine Reports Q1 EPS $(0.38) vs $(0.33) Est.,2016-05-09 16:48:00-04:00,LPCN,neutral
780362.0,Lipocine ReportsClinical Data For LPCN 1021At ENDO 2016 and ASA 41st Annual Conf.,2016-03-28 08:32:00-04:00,LPCN,neutral
780363.0,Lipocine Reports FY15 EPS $(1.11) vs. Est. $(1.12),2016-03-10 16:33:00-05:00,LPCN,neutral
780364.0,Lipocine Enters into a Commercial Manufacturing Services and Supply Agreement with M.W. Encap Ltd.,2016-03-04 11:04:00-05:00,LPCN,positive
780365.0,Lipocine Reports Positive Results of LPCN 1107 Study for the Prevention of Preterm Birth,2016-02-16 07:11:00-05:00,LPCN,positive
780366.0,Benzinga's Volume Movers,2015-11-16 12:17:00-05:00,LPCN,neutral
780367.0,Benzinga's Volume Movers,2015-11-13 10:23:00-05:00,LPCN,neutral
780368.0,Morning Market Gainers,2015-11-13 09:42:00-05:00,LPCN,neutral
780369.0,"Lipocene +16% After-Hours on Earnings Beat, Announcement of FDA PDUFA Date of June 28, 2016 to Complete Review of NDA for LPCN-1021",2015-11-12 17:19:00-05:00,LPCN,neutral
780370.0,Lipocine Reports Q3 EPS $(0.35) vs $(0.25) Est.,2015-11-12 16:12:00-05:00,LPCN,neutral
780371.0,Lipocine Reports Presentation of LPCN 1021 Data at SMSNA Meeting,2015-11-11 16:01:00-05:00,LPCN,neutral
780372.0,"FDA Accepts for Filing Lipocine's New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021",2015-10-29 16:23:00-04:00,LPCN,positive
780373.0,Lipocine Reports First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth,2015-09-28 09:01:00-04:00,LPCN,neutral
780374.0,Benzinga's Volume Movers,2015-08-31 10:42:00-04:00,LPCN,neutral
780375.0,"Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021",2015-08-31 09:03:00-04:00,LPCN,neutral
780376.0,"Empire Asset Management Raises PT On Lipocine To $25 From $18, Cites Lipocine Balance Sheet Strength As Means To 'accelerate its development programs' & Sees Potential For Commercialization Arrangements",2015-08-12 10:32:00-04:00,LPCN,positive
780377.0,Lipocine Reports Q2 Loss of $0.26/Share vs Loss of $0.20/Share Est.,2015-08-11 09:01:00-04:00,LPCN,negative
780378.0,"Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More",2015-07-22 14:29:00-04:00,LPCN,neutral
780379.0,Benzinga's Top Initiations,2015-07-22 09:55:00-04:00,LPCN,positive
780380.0,"Roth Capital Starts Lipocine, Pieris Pharma With Buy Ratings Amid Enormous Market Opportunity",2015-07-22 09:48:00-04:00,LPCN,positive
780381.0,Roth Capital Initiates Coverage on Lipocine at Buy,2015-07-22 08:09:00-04:00,LPCN,neutral
780382.0,"Lipcine:  Empire Asset Mgmt Says Company Is 'an easy pill to swallow', Initiates Buy WIth $18 PT",2015-07-16 11:07:00-04:00,LPCN,positive
780383.0,"Evercore Partners Initiates Coverage on Lipocine at Buy, Announces $18.00 PT",2015-07-16 11:05:00-04:00,LPCN,neutral
780384.0,Lipocine's Oral Testosterone top-line 52-week safety results from its Study of Oral Androgen Replacement pivotal Phase 3 clinical study,2015-06-29 16:02:00-04:00,LPCN,positive
780385.0,Benzinga's Top Initiations,2015-06-23 09:26:00-04:00,LPCN,positive
780386.0,"Canaccord Genuity Initiates Coverage on Lipocine at Buy, Announces $15.00 PT",2015-06-23 07:03:00-04:00,LPCN,neutral
780387.0,"Lipocine Announces Successful Completion of Food Effect Study for LPCN 1021, an Oral Testosterone Product Candidate",2015-06-15 09:03:00-04:00,LPCN,positive
780388.0,Lipocine Announces Development Plans for LPCN 1107,2015-06-08 09:02:00-04:00,LPCN,neutral
780389.0,Lipocine Attains FDA Orphan Drug Designationnfor LPCN 1107,2015-06-02 14:05:00-04:00,LPCN,neutral
780390.0,"Lipocine Receives FDA Orphan Drug Designation for LPCN 1107, an Oral Product Candidate for the Prevention of Preterm Birth",2015-06-02 14:03:00-04:00,LPCN,neutral
780391.0,Lipocine Shares Moving Higher as FDA Issues Orphan Drug Designation for Co.'s Pregnancy Candidate,2015-06-02 12:02:00-04:00,LPCN,positive
780392.0,Lipocine to Present Additional LPCN 1021 Clinical Data at American Urological Association Annual Meeting,2015-05-11 09:03:00-04:00,LPCN,neutral
780393.0,Lipocine Prices Offering of Common Stock at $6.50/Share,2015-04-29 16:01:00-04:00,LPCN,neutral
780394.0,Lipocine Prices 4.65M Shares at $6.50/Share,2015-04-24 08:30:00-04:00,LPCN,positive
780395.0,8-K from Lipocine Shows Registration for Common Stock Offering,2015-04-23 16:21:00-04:00,LPCN,neutral
780396.0,Lipocine Proposes Stock Offering,2015-04-23 16:01:00-04:00,LPCN,neutral
780397.0,Lipocine To Present Additional Phase 3 LPCN 1021 Clinical Data at American Society of Andrology 40th Annual Conference,2015-04-10 09:01:00-04:00,LPCN,neutral
780398.0,"Lipocine Announces Results From Pre-NDA Meeting for LPCN 1021, an Oral Testosterone Product Candidate",2015-03-24 09:01:00-04:00,LPCN,neutral
780399.0,Lipocine Reports FY14 Loss of $1.60/Share vs Loss of $1.53/Share Est.,2015-03-11 09:09:00-04:00,LPCN,negative
780400.0,Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015,2015-02-27 09:00:00-05:00,LPCN,neutral
780401.0,Lipocine Reports Presention of LPCN 1107 Clinical Data at SMFM Meeting,2015-01-30 09:03:00-05:00,LPCN,neutral
780402.0,"8-K from Lipocine Shows Positive Pharmacokinetic Data LPCN 1107, Data Shows Significant HPC Absorption After Oral Administration",2015-01-12 09:05:00-05:00,LPCN,positive
780403.0,FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021,2014-12-15 08:32:00-05:00,LPCN,neutral
780404.0,"Lipocine Director Ono Buys 4,000 Shares @$5.14/Share -Form 4",2014-11-19 15:26:00-05:00,LPCN,positive
780405.0,Lipocine Announces CTO Srinivasan Venkateshwaran Will Leave Company; Gerald Simmons Chief Business Development Officer To Leave,2014-11-17 08:17:00-05:00,LPCN,negative
780406.0,"Lipocine CEO Patel Buys 2,000 Shares @5.06/Share -Form 4",2014-11-14 11:38:00-05:00,LPCN,positive
780407.0,"Lipocine Director Hill Buys 4,000 Shares @$4.95/Share -Form 4",2014-11-13 11:43:00-05:00,LPCN,positive
780408.0,Lipocine Reports Q3 EPS of $(0.32) vs $(0.55) Est,2014-11-10 08:21:00-05:00,LPCN,neutral
780409.0,US Stock Futures Signal Higher Start On Wall Street,2014-10-13 07:28:00-04:00,LPCN,neutral
780410.0,Lipocine Announces Positive Top-Line Results In Phase 2a Study Of LPCN ,2014-10-13 07:05:00-04:00,LPCN,positive
780411.0,S-3 from Lipocine Shows Registration for $100M Mixed Securities Shelf Offering,2014-10-01 16:02:00-04:00,LPCN,positive
780412.0,Morning Market Movers ,2014-09-24 09:40:00-04:00,LPCN,neutral
780413.0,Lipocine Announces Positive Top-Line Results In Its Phase 3 Study of LPCN 1021 For Oral Testosterone Replacement Therapy,2014-09-24 08:33:00-04:00,LPCN,positive
780414.0,Benzinga's Top #PreMarket Gainers,2014-09-24 08:05:00-04:00,LPCN,positive
780415.0,"Shares of Lipocine Resume Trade, Stock Down 22.5%",2014-09-18 10:51:00-04:00,LPCN,positive
780416.0,"Shares of Lipocine Just Halted on Circuit Breaker, Stock Down 19.6%",2014-09-18 10:47:00-04:00,LPCN,positive
780417.0,"Shares of Lipocine Open for Trade, Not Yet Seeing an Updated Last Price",2014-09-17 18:30:00-04:00,LPCN,positive
780418.0,Shares of Lipocine to Resume Trade at 6:30 p.m. EDT,2014-09-17 18:26:00-04:00,LPCN,positive
780419.0,FDA Spokesperson Confirms FDA Advisory Panel Has Voted 20-1 FDA Should Revise Approved Uses of Testosterone Treatments,2014-09-17 17:09:00-04:00,LPCN,positive
780420.0,Several Sources on Twitter Suggesting FDA Advisory Panel Has Voted 20-1 FDA Needs to Revise Approved Uses for Testosterone Drugs,2014-09-17 16:45:00-04:00,LPCN,positive
780421.0,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone",2014-09-17 11:45:00-04:00,LPCN,positive
780422.0, Lipocine Halted: Pending News,2014-09-17 07:01:00-04:00,LPCN,neutral
780423.0,"Lipocine Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth",2014-09-08 16:00:00-04:00,LPCN,neutral
780424.0,Lipocine Reports Q2 EPS of $(0.55) vs $(0.42) Est,2014-08-13 16:00:00-04:00,LPCN,neutral
780425.0,Lipocine Announces Issuance Of U.S. Patent For LPCN 1021,2014-07-15 16:01:00-04:00,LPCN,neutral
780426.0,"Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy",2014-05-27 16:16:00-04:00,LPCN,positive
780427.0,Stocks Hitting 52-Week Lows,2014-05-27 11:01:00-04:00,LPCN,negative
780428.0,Lipocine Releases Successful Phase 1 1107 Results,2014-05-15 09:40:00-04:00,LPCN,positive
780429.0,Lipocine Annouces Successful Phase 1 LPCN 1107 Results,2014-05-15 08:42:00-04:00,LPCN,positive
780430.0,Lipocine Reports Q1 Loss of $0.41/Share,2014-05-13 08:39:00-04:00,LPCN,negative
